How can we optimize treatment of HER2-positive metastatic breast cancer?
Publication
, Journal Article
Hamilton, EP; Blackwell, KL
Published in: Oncology (Williston Park)
March 2013
Duke Scholars
Published In
Oncology (Williston Park)
ISSN
0890-9091
Publication Date
March 2013
Volume
27
Issue
3
Start / End Page
180 / 182
Location
United States
Related Subject Headings
- Receptor, erbB-2
- Receptor, ErbB-2
- Molecular Targeted Therapy
- Humans
- Female
- Breast Neoplasms
- Antineoplastic Agents
Citation
APA
Chicago
ICMJE
MLA
NLM
Hamilton, E. P., & Blackwell, K. L. (2013). How can we optimize treatment of HER2-positive metastatic breast cancer? Oncology (Williston Park), 27(3), 180–182.
Hamilton, Erika P., and Kimberly L. Blackwell. “How can we optimize treatment of HER2-positive metastatic breast cancer?” Oncology (Williston Park) 27, no. 3 (March 2013): 180–82.
Hamilton EP, Blackwell KL. How can we optimize treatment of HER2-positive metastatic breast cancer? Oncology (Williston Park). 2013 Mar;27(3):180–2.
Hamilton, Erika P., and Kimberly L. Blackwell. “How can we optimize treatment of HER2-positive metastatic breast cancer?” Oncology (Williston Park), vol. 27, no. 3, Mar. 2013, pp. 180–82.
Hamilton EP, Blackwell KL. How can we optimize treatment of HER2-positive metastatic breast cancer? Oncology (Williston Park). 2013 Mar;27(3):180–182.
Published In
Oncology (Williston Park)
ISSN
0890-9091
Publication Date
March 2013
Volume
27
Issue
3
Start / End Page
180 / 182
Location
United States
Related Subject Headings
- Receptor, erbB-2
- Receptor, ErbB-2
- Molecular Targeted Therapy
- Humans
- Female
- Breast Neoplasms
- Antineoplastic Agents